Carmot Therapeutics

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. The founding scientists are leaders in a class of anti-hormone drugs that are designed to block the relaxin hormone cellular signaling pathways in a number of different cancer types. Using the company's Relaxofen technology platform, therapeutic candidates are generated by engineering the natural relaxin peptide to display antagonistic properties. Through pre-clinical development and clinical trials, Medicor Biosciences plans to develop and potentially license the technology so that the therapeutics can be available for cancer patients as an anti-hormone therapy to impair the growth and spread of the disease.

Trana Discovery is a drug discovery technology company focused on identifying treatments for infections in human and agricultural applications. The company has a drug discovery technology platform that aids in discovering treatments for bacterial, viral, and fungal infectious diseases. Its technology involves screening compounds to find potential drug candidates that inhibit the target pathogen's use of transfer RNA, which is necessary for their propagation. It was founded in 2000 and is based in Cary, North Carolina.

InterveXion Therapeutics is a privately held clinical-stage biotech company focused on developing therapies for methamphetamine use disorder. The company offers a range of treatments including short and long-acting monoclonal antibodies and vaccines designed to prevent methamphetamine from entering the central nervous system. InterveXion's lead product is in Phase 2 clinical development for treating methamphetamine use disorder and overdose, supported by grants from the National Institute on Drug Abuse. It was founded in 2002 and is based in Little Rock, Arkansas.

GNI is a pharmaceutical development company that focuses on creating new drug targets and pharmaceutical agents. The company employs gene regulatory network methodologies and systems biology to develop drugs that aim to improve treatment outcomes compared to traditional genomic methods. GNI's primary areas of focus include infectious diseases, cancer, and cardiovascular conditions. It is based in Japan.

Melior Discovery focuses on preclinical drug development in the life sciences industry. The company provides in vivo pharmacology services, including access to validated disease models and platforms for drug repositioning and repurposing. Melior Discovery works with clients in the pharmaceutical and biopharmaceutical sectors. It was founded in 2005 and is based in Exton, Pennsylvania.